Carmell Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Selling, General & Admin	2.62	3.22	0.86
Research & Development	2.5	2.2	0.98
Other Operating Expenses	0.82	0.09	0.09
Operating Expenses	5.94	5.51	1.94
Operating Income	-5.94	-5.51	-1.94
Interest Expense / Income	0.85	1.7	0.72
Other Expense / Income	8.65	1.84	3.82
Pretax Income	-15.45	-9.05	-6.48
Net Income	-15.45	-9.05	-6.48
Preferred Dividends	0.68	0.56	0.31
Net Income Common	-16.12	-9.61	-6.79
Shares Outstanding (Basic)	11	2	23
Shares Outstanding (Diluted)	11	2	23
Shares Change	527.34%	-92.41%	-
EPS (Basic)	-1.46	-5.47	-0.29
EPS (Diluted)	-1.46	-5.47	-0.29
Free Cash Flow	-8.38	-3.44	-1.18
Free Cash Flow Per Share	-0.76	-1.96	-0.05
EBITDA	-14.47	-7.1	-5.52
Depreciation & Amortization	0.12	0.24	0.24
EBIT	-14.59	-7.35	-5.76

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).